

**Supplementary Table 1:** Characteristics of patients assessed for anti-cardiac troponin I antibody detection.

Cardiac adverse event	ICI	Age	Sex	Cardiovascular risk factors and history	Anti-cardiac troponin I antibody detection
Left ventricular systolic dysfunction	Nivolumab	Male	80	Tobacco, dyslipidemia, hypertension, silent myocardial infarction, peripheral arterial disease	Present
Left ventricular systolic dysfunction	Nivolumab	Male	74	Dyslipidemia, peripheral arterial disease	Present
Left ventricular systolic dysfunction	Avelumab	Male	62	Tobacco, dyslipidemia, hypertension, type 2 diabetes, stable coronary disease	Absent
Atrial fibrillation	Nivolumab	Male	64	Hypertension, type 2 diabetes, stable coronary disease	Absent
Control (no event)	Nivolumab	Male	62	Tobacco, hypertension, ischemic stroke	Absent
Control (no event)	Pembrolizumab	Female	70	Tobacco, dyslipidemia	Absent
Control (no event)	Pembrolizumab	Male	75	Tobacco, type 2 diabetes	Absent
Control (no event)	Nivolumab	Female	63	Tobacco	Absent